Our Publications
As a science-driven company, we proudly publish numerous scientific papers every year in high-impact journals. Please feel free to contact our Science-team if you have questions or comments to our publications, or proposals for new scientific collaborations: science@nbcd.com2 publications found
July 25, 2016
This randomized, double-blind, placebo-controlled phase III study was conducted to assess the efficacy and safety of oral calcitonin (SMC021) for the treatment of postmenopausal osteoporosis. A total of 4665 postmenopausal women with osteoporosis were randomized 1:1 to receive calcium and vitamin D plus either SMC021 tablets (0.8mg/d) or placebo for 36months. The primary endpoint was the proportion of patients with a new vertebral fracture.
Journals:
Bone
Authors:
Henriksen K
, Byrjalsen I
, Andersen JR
, Bihlet AR
, Russo LA
, Alexandersen P
, Valter I
, Qvist P
, Lau E
, Riis BJ
, Christiansen C
, Karsdal MA
, SMC021 investigators
Osteoporosis
December 09, 2012
Treatment of osteoporosis with subcutaneous (SC) injections of rhPTH(1-34) or rhPTH(1-84) is associated with significant improvements in BMD and reductions in osteoporotic fractures. However, subcutaneous injections can be associated with discomfort and thus deteriorating compliance.
The UGL-OR1001 trial aimed to establish the efficacy and safety parameters of a novel oral tablet formulation of rhPTH(1-31)NH(2) and matching placebo tablets and open-label teriparatide positive control in postmenopausal women with osteoporosis.
Journals:
Bone
Authors:
Henriksen K
, Andersen JR
, Riis BJ
, Mehta N
, Tavakkol R
, Alexandersen P
, Byrjalsen I
, Valter I
, Nedergaard BS
, Teglbjaerg CS
, Stern W
, Sturmer A
, Mitta S
, Nino AJ
, Fitzpatrick LA
, Christiansen C
, Karsdal MA
Osteoporosis